Skip to main content
Erschienen in: Familial Cancer 2/2014

01.06.2014 | Original Article

Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes

verfasst von: Thereasa A. Rich, Mei Liu, Carol J. Etzel, Sarah A. Bannon, Maureen E. Mork, Kaylene Ready, Devki S. Saraiya, Elizabeth G. Grubbs, Nancy D. Perrier, Karen H. Lu, Banu K. Arun, Terri L. Woodard, Leslie R. Schover, Jennifer K. Litton

Erschienen in: Familial Cancer | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Preimplantation genetic diagnosis (PGD) allows couples to avoid having a child with an inherited condition, potentially reducing cancer burden in families with a hereditary cancer predisposition. This study investigated and compared awareness and acceptance of PGD among patients with different hereditary cancer syndromes. Questionnaires were mailed to 984 adults with hereditary breast and ovarian cancer, Lynch syndrome, familial adenomatous polyposis, or multiple endocrine neoplasia type 1 or 2. Associations between clinical, demographic, and psychosocial factors and awareness and acceptance of PGD were examined. Of 370 respondents (38 % return rate), 28 % felt their syndrome impacted family planning, 24 % were aware of PGD, 72 % felt that PGD should be offered, 43 % would consider using PGD, and 29 % were uncertain. Family experience and syndrome-specific characteristics, such as disease severity, quality of life and availability of medical interventions as well as gender, family planning stage, and religiosity impact perceptions of the acceptability of PGD, though a high level of uncertainty exists. Hereditary cancer patients lack awareness of PGD despite feeling that PGD should be offered, highlighting the need for education on this topic. While we found attitudes about the acceptability of PGD to be generally similar to those reported in the literature and of genetics and ethics experts, we observed similarities and differences between syndromes that provide insight into why some hereditary cancer patients may find PGD more acceptable than others.
Literatur
1.
Zurück zum Zitat Offit K et al (2006) Cancer genetic testing and assisted reproduction. J Clin Oncol 24(29):4775–4782PubMedCrossRef Offit K et al (2006) Cancer genetic testing and assisted reproduction. J Clin Oncol 24(29):4775–4782PubMedCrossRef
2.
Zurück zum Zitat The Council on Ethical and Judicial Affairs A.M.A (1994) Ethical issues related to prenatal genetic testing. Arch Fam Med 3(7):633–642CrossRef The Council on Ethical and Judicial Affairs A.M.A (1994) Ethical issues related to prenatal genetic testing. Arch Fam Med 3(7):633–642CrossRef
3.
Zurück zum Zitat Ford D et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62(3):676–689PubMedCentralPubMedCrossRef Ford D et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62(3):676–689PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643–646PubMedCrossRef King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643–646PubMedCrossRef
6.
Zurück zum Zitat Antoniou A et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130PubMedCentralPubMedCrossRef Antoniou A et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Petersen GM, Slack J, Nakamura Y (1991) Screening guidelines and premorbid diagnosis of familial adenomatous polyposis using linkage. Gastroenterology 100(6):1658–1664PubMed Petersen GM, Slack J, Nakamura Y (1991) Screening guidelines and premorbid diagnosis of familial adenomatous polyposis using linkage. Gastroenterology 100(6):1658–1664PubMed
9.
Zurück zum Zitat Howe JR, Norton JA, Wells SA Jr (1993) Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. Surgery 114(6):1070–1077PubMed Howe JR, Norton JA, Wells SA Jr (1993) Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. Surgery 114(6):1070–1077PubMed
10.
Zurück zum Zitat Brandi ML et al (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86(12):5658–5671PubMedCrossRef Brandi ML et al (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86(12):5658–5671PubMedCrossRef
11.
Zurück zum Zitat Kouvaraki MA et al (2006) Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg 30(5):643–653PubMedCrossRef Kouvaraki MA et al (2006) Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg 30(5):643–653PubMedCrossRef
12.
Zurück zum Zitat Arvanitis ML et al (1990) Mortality in patients with familial adenomatous polyposis. Dis Colon Rectum 33(8):639–642PubMedCrossRef Arvanitis ML et al (1990) Mortality in patients with familial adenomatous polyposis. Dis Colon Rectum 33(8):639–642PubMedCrossRef
13.
Zurück zum Zitat Dekeuwer C, Bateman S (2013) Much more than a gene: hereditary breast and ovarian cancer, reproductive choices and family life. Med Health Care Philos 16(2):231–244PubMedCrossRef Dekeuwer C, Bateman S (2013) Much more than a gene: hereditary breast and ovarian cancer, reproductive choices and family life. Med Health Care Philos 16(2):231–244PubMedCrossRef
14.
Zurück zum Zitat Hurley K et al (2012) Incorporating information regarding preimplantation genetic diagnosis into discussions concerning testing and risk management for BRCA1/2 mutations: a qualitative study of patient preferences. Cancer 118(24):6270–6277PubMedCrossRef Hurley K et al (2012) Incorporating information regarding preimplantation genetic diagnosis into discussions concerning testing and risk management for BRCA1/2 mutations: a qualitative study of patient preferences. Cancer 118(24):6270–6277PubMedCrossRef
15.
Zurück zum Zitat Julian-Reynier C et al (2012) BRCA1/2 carriers: their childbearing plans and theoretical intentions about having preimplantation genetic diagnosis and prenatal diagnosis. Genet Med 14(5):527–534PubMedCrossRef Julian-Reynier C et al (2012) BRCA1/2 carriers: their childbearing plans and theoretical intentions about having preimplantation genetic diagnosis and prenatal diagnosis. Genet Med 14(5):527–534PubMedCrossRef
16.
Zurück zum Zitat Ormondroyd E et al (2012) Attitudes to reproductive genetic testing in women who had a positive BRCA test before having children: a qualitative analysis. Eur J Hum Genet 20(1):4–10PubMedCentralPubMedCrossRef Ormondroyd E et al (2012) Attitudes to reproductive genetic testing in women who had a positive BRCA test before having children: a qualitative analysis. Eur J Hum Genet 20(1):4–10PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Quinn GP et al (2010) BRCA carriers’ thoughts on risk management in relation to preimplantation genetic diagnosis and childbearing: when too many choices are just as difficult as none. Fertil Steril 94(6):2473–2475PubMedCrossRef Quinn GP et al (2010) BRCA carriers’ thoughts on risk management in relation to preimplantation genetic diagnosis and childbearing: when too many choices are just as difficult as none. Fertil Steril 94(6):2473–2475PubMedCrossRef
18.
Zurück zum Zitat Quinn GP et al (2009) Decisions and ethical issues among BRCA carriers and the use of preimplantation genetic diagnosis. Minerva Med 100(5):371–383PubMed Quinn GP et al (2009) Decisions and ethical issues among BRCA carriers and the use of preimplantation genetic diagnosis. Minerva Med 100(5):371–383PubMed
19.
Zurück zum Zitat Vadaparampil ST et al (2009) Factors associated with preimplantation genetic diagnosis acceptance among women concerned about hereditary breast and ovarian cancer. Genet Med 11(10):757–765PubMedCrossRef Vadaparampil ST et al (2009) Factors associated with preimplantation genetic diagnosis acceptance among women concerned about hereditary breast and ovarian cancer. Genet Med 11(10):757–765PubMedCrossRef
20.
Zurück zum Zitat Quinn GP et al (2009) Conflict between values and technology: perceptions of preimplantation genetic diagnosis among women at increased risk for hereditary breast and ovarian cancer. Fam Cancer 8(4):441–449PubMedCrossRef Quinn GP et al (2009) Conflict between values and technology: perceptions of preimplantation genetic diagnosis among women at increased risk for hereditary breast and ovarian cancer. Fam Cancer 8(4):441–449PubMedCrossRef
21.
Zurück zum Zitat Quinn G et al (2009) Attitudes of high-risk women toward preimplantation genetic diagnosis. Fertil Steril 91(6):2361–2368PubMedCrossRef Quinn G et al (2009) Attitudes of high-risk women toward preimplantation genetic diagnosis. Fertil Steril 91(6):2361–2368PubMedCrossRef
22.
Zurück zum Zitat Fortuny D et al (2009) Opinion about reproductive decision making among individuals undergoing BRCA1/2 genetic testing in a multicentre Spanish cohort. Hum Reprod 24(4):1000–1006PubMedCrossRef Fortuny D et al (2009) Opinion about reproductive decision making among individuals undergoing BRCA1/2 genetic testing in a multicentre Spanish cohort. Hum Reprod 24(4):1000–1006PubMedCrossRef
23.
Zurück zum Zitat SenGupta SB, Vadaparampil ST, Menon U (2012) Preimplantation genetic diagnosis for hereditary cancers. Adv Exp Med Biol 732:103–113PubMedCrossRef SenGupta SB, Vadaparampil ST, Menon U (2012) Preimplantation genetic diagnosis for hereditary cancers. Adv Exp Med Biol 732:103–113PubMedCrossRef
24.
Zurück zum Zitat Douma KF et al (2010) Attitudes toward genetic testing in childhood and reproductive decision-making for familial adenomatous polyposis. Eur J Hum Genet 18(2):186–193PubMedCentralPubMedCrossRef Douma KF et al (2010) Attitudes toward genetic testing in childhood and reproductive decision-making for familial adenomatous polyposis. Eur J Hum Genet 18(2):186–193PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Quinn GP et al (2010) High risk men’s perceptions of pre-implantation genetic diagnosis for hereditary breast and ovarian cancer. Hum Reprod 25(10):2543–2550PubMedCrossRef Quinn GP et al (2010) High risk men’s perceptions of pre-implantation genetic diagnosis for hereditary breast and ovarian cancer. Hum Reprod 25(10):2543–2550PubMedCrossRef
26.
Zurück zum Zitat Staton AD et al (2008) Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. Fam Cancer 7(2):179–186PubMedCrossRef Staton AD et al (2008) Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. Fam Cancer 7(2):179–186PubMedCrossRef
28.
Zurück zum Zitat Quinn GP et al (2012) High-risk consumers’ perceptions of preimplantation genetic diagnosis for hereditary cancers: a systematic review and meta-analysis. Genet Med 14(2):191–200PubMedCrossRef Quinn GP et al (2012) High-risk consumers’ perceptions of preimplantation genetic diagnosis for hereditary cancers: a systematic review and meta-analysis. Genet Med 14(2):191–200PubMedCrossRef
29.
Zurück zum Zitat Kastrinos F et al (2007) Attitudes toward prenatal genetic testing in patients with familial adenomatous polyposis. Am J Gastroenterol 102(6):1284–1290PubMedCrossRef Kastrinos F et al (2007) Attitudes toward prenatal genetic testing in patients with familial adenomatous polyposis. Am J Gastroenterol 102(6):1284–1290PubMedCrossRef
30.
Zurück zum Zitat Menon U et al (2007) Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer. Hum Reprod 22(6):1573–1577PubMedCrossRef Menon U et al (2007) Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer. Hum Reprod 22(6):1573–1577PubMedCrossRef
31.
Zurück zum Zitat Julian-Reynier C et al (2009) Professionals assess the acceptability of preimplantation genetic diagnosis and prenatal diagnosis for managing inherited predisposition to cancer. J Clin Oncol 27(27):4475–4480PubMedCrossRef Julian-Reynier C et al (2009) Professionals assess the acceptability of preimplantation genetic diagnosis and prenatal diagnosis for managing inherited predisposition to cancer. J Clin Oncol 27(27):4475–4480PubMedCrossRef
32.
Zurück zum Zitat Brandberg Y et al (2008) Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol 26(24):3943–3949PubMedCrossRef Brandberg Y et al (2008) Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol 26(24):3943–3949PubMedCrossRef
33.
Zurück zum Zitat Meister U et al (2005) Knowledge and attitudes towards preimplantation genetic diagnosis in Germany. Hum Reprod 20(1):231–238PubMedCrossRef Meister U et al (2005) Knowledge and attitudes towards preimplantation genetic diagnosis in Germany. Hum Reprod 20(1):231–238PubMedCrossRef
34.
Zurück zum Zitat Krones T et al (2005) Public, expert and patients’ opinions on preimplantation genetic diagnosis (PGD) in Germany. Reprod Biomed Online 10(1):116–123PubMedCrossRef Krones T et al (2005) Public, expert and patients’ opinions on preimplantation genetic diagnosis (PGD) in Germany. Reprod Biomed Online 10(1):116–123PubMedCrossRef
35.
Zurück zum Zitat Fertility preservation and reproduction in cancer patients. Fertil Steril, 2005. 83(6): 1622–1628 Fertility preservation and reproduction in cancer patients. Fertil Steril, 2005. 83(6): 1622–1628
36.
Zurück zum Zitat Loren AW et al (2013) Fertility preservation for patients with cancer: american society of clinical oncology clinical practice guideline update. J Clin Oncol 31(19):2500–2510PubMedCrossRef Loren AW et al (2013) Fertility preservation for patients with cancer: american society of clinical oncology clinical practice guideline update. J Clin Oncol 31(19):2500–2510PubMedCrossRef
37.
Zurück zum Zitat Brandt AC et al (2010) Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes. Fam Cancer 9(3):479–487PubMedCrossRef Brandt AC et al (2010) Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes. Fam Cancer 9(3):479–487PubMedCrossRef
Metadaten
Titel
Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes
verfasst von
Thereasa A. Rich
Mei Liu
Carol J. Etzel
Sarah A. Bannon
Maureen E. Mork
Kaylene Ready
Devki S. Saraiya
Elizabeth G. Grubbs
Nancy D. Perrier
Karen H. Lu
Banu K. Arun
Terri L. Woodard
Leslie R. Schover
Jennifer K. Litton
Publikationsdatum
01.06.2014
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 2/2014
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-013-9685-0

Weitere Artikel der Ausgabe 2/2014

Familial Cancer 2/2014 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.